Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$24.99
▲ $0.01 (+0.0%)
Market data updated: 08/05 02:47 AM
Fundamentals updated: 08/05/2026
News analyzed: 09/17/2026
Market Cap
$1.17B
Day Range
$24.98 - $25.00
52-Week Range
$9.30 - $25.49
Beta
—
Next Earnings
03.11.2026
AVNS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+152.7% (1Y)
Strengths: 14/28 factors positiveRisk: Low
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 81.6%
Growth
Biggest negative driver
Operating margin
Operating margin: -8.8% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
47
Value
50
Momentum
49
Risk
70
Sentiment
50
Fundamental
39
Institutional
No data available
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Avanos Medical Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 1 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
28
🎯 Conviction (vs. Emotion)
37
Psychology
60
Fundamentals
39
Technical
49
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+1%
Market Narrative
44
Fundamental Reality
37
Narrative Gap
+7
📈 3D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Morgan Housel — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 11/100
Morgan Housel
The Psychology of Money (2020)
🟢 100
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 87
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 83
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 67
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 63
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 63
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 61
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 53
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 45
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 40
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 36
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 34
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 30
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 12
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 11
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 241 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (5 bullish · 6 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid distribution phase — a trading range after an advance with declining volume.
Medium confidence
$24.46
Range Bottom
$25.49
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
50.5%
Operating Margin
-8.8%
Net Margin
-10.4%
EBITDA Margin
—
ROE
-9.4%
ROA
-6.8%
ROIC
—
EPS
-$1.57
Cash
$89.80M
Total Debt
$100.50M
Current Ratio
2.15
Debt/Equity
0.13
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$16.75
Tangible Book Value per Share (Tangible NAV)
$14.22
Sentiment based on basic keywords (not AI) — 0 positive, 1 neutral, 0 negative out of the last 1 articles.
Benzinga · 20.7.2026
Avanos Medical Inc. (AVNS) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AVNS currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
AVNS's technical score is 49/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 81.6%; Net income growth: 81.4%; ATR: 0.3% of price.
Based on the real signals StockIQ computed: Operating margin: -8.8% (negative); Net margin: -10.4% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for AVNS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Galovan Scott Michael | Grant/Award from Employer | 27.7.2026 | 96,121 | +96,121 | — |
| OLEARY PATRICK J | Disposition to the Company | 27.7.2026 | 0 | -54,640 | $25.00 |
| Galovan Scott Michael | Disposition to the Company | 27.7.2026 | 0 | -135,596 | $25.00 |
| Delgado Sigfrido | Disposition to the Company | 27.7.2026 | 0 | -55,741 | $25.00 |
| BLACKFORD GARY | Disposition to the Company | 27.7.2026 | 0 | -40,000 | $25.00 |
| Pacitti David | Disposition to the Company | 27.7.2026 | 0 | -322,194 | $25.00 |
| Delgado Sigfrido | Grant/Award from Employer | 27.7.2026 | 54,886 | +54,886 | — |
| Shimer Julie Ann | Disposition to the Company | 27.7.2026 | 0 | -50,090 | $25.00 |
| Pacitti David | Grant/Award from Employer | 27.7.2026 | 444,730 | +444,730 | — |
| Franchini Indrani Lall | Disposition to the Company | 27.7.2026 | 0 | -4,817 | $25.00 |
| Egbuonu-Davis Lisa | Disposition to the Company | 27.7.2026 | 0 | -13,811 | $25.00 |
| OLEARY PATRICK J | Grant/Award from Employer | 8.5.2026 | 12,003 | +12,003 | — |
| BLACKFORD GARY | Grant/Award from Employer | 8.5.2026 | 12,003 | +12,003 | — |
| Franchini Indrani Lall | Grant/Award from Employer | 8.5.2026 | 12,003 | +12,003 | — |
| Egbuonu-Davis Lisa | Grant/Award from Employer | 8.5.2026 | 12,003 | +12,003 | — |
| Shimer Julie Ann | Grant/Award from Employer | 8.5.2026 | 12,003 | +12,003 | — |
| Delgado Sigfrido | Tax Withholding in Shares | 22.4.2026 | 55,741 | -4,264 | $24.64 |
| Galovan Scott Michael | Tax Withholding in Shares | 22.4.2026 | 135,596 | -4,228 | $24.64 |
| Pacitti David | Tax Withholding in Shares | 14.4.2026 | 322,194 | -21,194 | $14.53 |
| Delgado Sigfrido | Grant/Award from Employer | 13.3.2026 | 60,005 | +15,886 | — |
| Delgado Sigfrido | Grant/Award from Employer | 13.3.2026 | 59,434 | +37,520 | — |
| Galovan Scott Michael | Grant/Award from Employer | 13.3.2026 | 139,824 | +29,481 | — |
| Galovan Scott Michael | Grant/Award from Employer | 13.3.2026 | 96,212 | +69,630 | — |
| Pacitti David | Grant/Award from Employer | 13.3.2026 | 343,388 | +101,341 | — |
| Pacitti David | Grant/Award from Employer | 13.3.2026 | 239,354 | +239,354 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,751,047 shares short as of 2026-07-15 · vs. 1,751,047 on 2026-07-14
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
Full breakdown of every data type and its source: Data Sources · Methodology